Gluckman E, Lotsberg J, Devergie A, Zhao X M, Melo R, Gomez-Morales M, Nebout T, Mazeron M C, Perol Y
Lancet. 1983 Sep 24;2(8352):706-8. doi: 10.1016/s0140-6736(83)92248-1.
In a double-blind controlled study, oral acyclovir was compared with placebo in 39 consecutive patients undergoing bone-marrow transplantation. Acyclovir was given at a dose of 200 mg every 6 h from 8 days before to 35 days after bone-marrow transplantation. Pharmacokinetic studies showed good absorption of the drug, despite intestinal damage related to chemoradiotherapy or gut graft-versus-host disease. There was no sign of toxicity. The protection against herpes simplex virus (HSV) infection was complete in the treated group compared with the placebo group even in patients with high anti-HSV antibody titres before transplantation. The same protection was observed against cytomegalovirus (CMV) infection. The frequencies of HSV and CMV infections were the same in both groups after the cessation of treatment.
在一项双盲对照研究中,对39例接受骨髓移植的连续患者比较了口服阿昔洛韦与安慰剂的效果。从骨髓移植前8天至移植后35天,每6小时给予阿昔洛韦200毫克。药代动力学研究表明,尽管存在与放化疗或肠道移植物抗宿主病相关的肠道损伤,但该药物的吸收良好。未出现毒性迹象。与安慰剂组相比,治疗组对单纯疱疹病毒(HSV)感染的预防是完全的,即使是移植前抗HSV抗体滴度较高的患者。对巨细胞病毒(CMV)感染也观察到了同样的保护作用。治疗停止后,两组中HSV和CMV感染的频率相同。